PT-141 Benefits: Labelled Use, Trials and Reports
PT-141 (bremelanotide, Vyleesi) benefits: HSDD trial results, what anonymous users report, and limits for men/ED. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
The documented benefit of PT-141 (bremelanotide) is for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women — the FDA-approved Vyleesi indication. In the RECONNECT trials, bremelanotide improved desire scores and reduced distress versus placebo over 24 weeks, without a significant increase in satisfying sexual events. Nausea affected about 40% of treated participants. It is not approved for male erectile dysfunction and is not authorised in Canada. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Benefits vs non-benefits (label and trials)
| Claimed benefit | What evidence supports |
|---|---|
| Increased sexual desire (HSDD, premenopausal women) | RECONNECT phase 3 trials; FDA-labelled use for Vyleesi |
| Less distress about low desire | Supported in the same trials |
| More satisfying sexual events | Not significantly increased vs placebo in those trials |
| Male ED "Viagra alternative" | Not an approved ED drug; mechanism is central desire, not PDE5 blood flow |
What users report here
#297, #193 and #117 describe desire returning when PDE5 pills only helped mechanics. #279 describes nausea dominating the evening. Full context: PT-141 and PT-141 side effects. Duration questions: how long does PT-141 last.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- What are the benefits of PT-141?
- In labelled use, modest improvements in desire and desire-related distress for premenopausal women with HSDD. Nausea is common.
- Does PT-141 help men?
- It is not approved for men. Anecdotes exist; they are not trial proof for male ED.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.